狄诺塞麦与双麟酸盐治疗糖皮质激素性骨质疏松症疗效性与安全性的Meta分析  

The efficacy and safety of denosumab and bisphosphonates on glucocorticoid induced osteoporosis patients:a meta-analysis

作　　者：谢静 严晓旭 马凤莲 刘媛媛 陈曦 蔡利军[2] 牛东生[2] 吕金捍[2] 郭东更[1] Xie Jing;Yan Xiaoxu;Ma Fenglian;Liu Yuanyuan;Chen Xi;Cai Lijun;Niu Dongsheng;Lyu Jinhan;Guo Donggeng(Department of Rheumatism,People's Hospital of Ningxia Hui Autonomous Region (the First Clinical College Affiliated to Northwest Minzu University) Autonomous Region People's Hospital Affiliated to Ningxia Medical University,Yinchuan 750001,China;Ningxia Bone and Joint Disease Clinical Medical Research Center,People's Hospital of Ningxia Hui Autonomous Region (the First Clinical College Affiliated to Northwest Minzu University) Autonomous Region People's Hospital Affiliated to Ningxia Medical University,Yinchuan 750001,China)

机构地区：[1]宁夏回族自治区人民医院(西北民族大学附属第一临床学院)宁夏医科大学附属自治区人民医院风湿免疫科,银川750001 [2]宁夏回族自治区人民医院(西北民族大学附属第一临床学院)宁夏医科大学附属自治区人民医院宁夏骨与关节疾病临床医学研究中心,银川750001

出　　处：《中国医师进修杂志》2019年第10期869-874,共6页Chinese Journal of Postgraduates of Medicine

基　　金：国家自然科学基金(31460293);国家自然科学基金(81760299);国家自然科学基金(81360272);宁夏自然科学基金(NZ14164);宁夏回族自治区科技惠民专项项目(2018CMG03002).

摘　　要：目的评价狄诺塞麦与双膦酸盐类药物治疗糖皮质激素性骨质疏松患者疗效及安全性比较.方法通过检索CNKI、CBM、VIP、万方、Pubmed、Embase及Cochrane数据库获得符合标准的研究.结果最终纳入3篇随机对照试验,共计869例患者,数据分析结果显示,与双膦酸盐组比较,狄诺塞麦组腰椎、髋关节、股骨颈骨密度分别升高2.47%、1.43%、1.07%,而不良反应及严重不良反应发生率相当.结论与双膦酸盐组比较,狄诺塞麦组在升高骨密度方面具有优势,且不良反应发生风险不高.Objective In order to evaluate the therapeutic effects and safety of denosumab and bisphosphonates in glucocorticoid induced osteoporosis patients. Methods Standard studies were obtained by searching CNKI, CBM, VIP, Wanfang, Pubmed, Embase and Cochrane databases. Results Three RCTs with 869 patients were included in this study. It showed that the mean changes of lumbar spine, total hip and femoral neck bone mineral density (BMD) for patients in denosumab group were increased by 2.47%, 1.43% and 1.07% respectively compared to those of bisphosphonates group.There was no statistically significant difference between patients receiving denosumab and those receiving bisphosphonate in terms of adverse events and serious adverse events. Conclusions Denosumab has an effective increase for lumbar spine, total hip and femoral neck bone mineral density, and the safety of both is similar.

关 键 词：骨质疏松 META分析 狄诺塞麦 双膦酸盐 

分 类 号：R580[医药卫生—内分泌]